The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Extranodal involvement reveals distinct efficacy outcomes with CAR-T in large B-cell lymphoma
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the impact of extranodal involvement in patients with lymphoma treated with CAR T-cell therapies. Dr Barba notes that patients with isolated extranodal involvement performed similarly to those with nodal involvement, while those with both extranodal and nodal involvement had poorer outcomes.This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
